Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-14
2006-11-14
Richter, Johann (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S317500
Reexamination Certificate
active
07135492
ABSTRACT:
Antiatherosclerotic compounds of Formula I are provided:wherein:R is lower alkyl, alkenyl, alkynyl, or —O—(CH2)n—COOR′;R′ is lower alkyl;n is an integer of 1–3;Ar is phenyl, or phenyl substituted with one or more of halogen, lower alkyl, alkenyl, alkynyl, alkoxy, perfluoroalkyl, perfluoroalkoxy, or alkylthio; and pharmaceutically acceptable salts thereof.
REFERENCES:
patent: 3461133 (1969-08-01), Stoffel
patent: 4084001 (1978-04-01), Durant et al.
patent: 4152453 (1979-05-01), Durant et al.
patent: 5312919 (1994-05-01), Gulliya et al.
patent: 2003/0119890 (2003-06-01), Batera et al.
patent: 0154 819 (1982-04-01), None
patent: 219 483 (1985-03-01), None
patent: 3540919 (1987-05-01), None
patent: 0 718 290 (2002-04-01), None
Wanda Zankowska-Jasinska et al., Polish Journal of Pharmacology, “1,3-disubstituted 2-thioxo-4,5-imidazolidinediones and 2,4,5-imidazolidinetriones and their anticonvulsant activity” 1990, pp. 59-68.
R. Beckert et al., Journal Fuer Praktische Chemie (1990) 331 (I), pp. 65-82; and Journal Fuer Praktische Chemie (1982) 324 (2) pp. 227-236.
Barr, David P., et al. American Journal of Medicine, 11, 480-493 (1951).
Miller, J.G., et al., The Lancet, 1, 16-19 (1975).
Gordon, David J., et al., Circulation, 79(1), 8-15 (1989).
Stampfer, Meir J., et al., New England Journal of Medicine, 325(6), 373-381 (1991).
Baidmon, Juan Jose, et al., Laboratory Investigation, 60(3), 455-461 (1989).
Miller N.E., et al., British Medical Journal, 282, 1741-1744 (1981).
Picardo, Martino et al., Arteriosclerosis, 6(4), 434-441 (1986).
Glomset, John A., Journal of Lipid Research, 9, 155-167 (1968).
Glass, Christopher K., et al., The Journal of Biological Chemistry, 258(11), 7161-7167 (1983).
Mackinnon, Malcolm, et al., The Journal of Biological Chemistry, 261(6), 2548-2552 (1986).
Grow, Thomas E., et al., The Journal of Biological Chemistry, 8034-8041 (1978).
Lagocki, Peter A., et al., The Journal of Biological Chemistry, 255(8), (1980).
Kieft, Karen A., et al., Journal of Lipid Research, 32, 859-866 (1991).
Schaefer, Ernst J., et al., Journal of Lipid Research, 23, 1259-1273 (1982).
Gofman, John W., et al., Circulation, 34, 679-697 (1966).
Aguilar-Bryan et al., “Toward Understanding the Assembly and Structure of KATPChannels”,Physiological Reviews, 78:227-245 (1998).
Atwal, “Modulation of Potassium Channels by Organic Molecules”,Medicinal Research Reviews, 12(6):569-591 (1992).
Beckert et al., “Reaction of oxalic amidines with carbonic acid derived heterocumulenes to imidazolidine derivatives”,Journal fuer Praktische Chemie, 332(1):65-82 (1990) (Abstract only CAPLUS Accession No. 1990:497511; Document No. 113:97511).
Bonev et al., “ATP-sensitive potassium channels in smooth muscle cells from guinea pig urinary bladder”,Am. J. Physiol.. 264:C1190-C1200 (1993).
Evans et al., “Potassium Channel Activators: Pharmacological Methods, Models, and Structure-Activity Relationships”,Progress in Medicinal Chemistry, 31:411-447 (1994).
Fujii et al., “Potassium channel blockers and the effects of cromakalim on the smooth muscle of the guinea-pig bladder”,Br. J. Pharmacol., 99:779-785 (1990).
Garcia et al., “Pharmacology of Potassium Channels”,Advances in Pharmacology, 39:425-471 (1997).
Gopalakrishnan et al., “ATP-Sensitive K+Channels: Pharmacologic Properties, Regulation and Therapeutic Potential”,Drug Development Research, 28:95-127 (1993).
Grant et al., “Effect of K+Channel Blockers and Cromakalim (BRL 34915) on the Mechanical Activity of Guinea Pig Detrusor Smooth Muscle”,J. Pharmacol. Exp. Thera., 259(3):1158-1164 (1991).
Lawson, “Potassium Channel Activation: A Potential Therapeutic Approach?”,Pharmacol. Ther., 70:39-63. (1996).
Malmgren et al., “Effects of Cromakalim (BRL 34915) and Pinacidil on Normal and Hypertrophied Rat Detrusor in Vitro”,The Journal of Urology, 143:828-834 (1990).
Malmgren et al., “Effects of Pinacidil and Cromakalim (BRL 34915) on Bladder Function in Rats with Detrusor Instability”,The Journal of Urology, 142:1134-1138 (1989).
McDonough et al., “Overview of the Relationship Between Structure and Function in Ion Channels”,Drug Development Research, 33:190-202 (1994).
Zankowska-Jasinska et al., “1,3-Disubstituted 2-thioxo-4, 5-imidazolidinediones and 2,4,5-imidazolidinetriones and their anticonvulsant activity”,Polish Journal of Pharmacology and Pharmacy, 42(1):59-68 (1990) (Abstract only CAPLUS Accession No. 1991:75036; Document No. 1144:75036).
Elokdah Hassan M.
Sulkowski Theodore S.
Fish & Richardson P.C.
Richter Johann
Sackey Ebenezer
Wyeth
LandOfFree
1,3-disubstituted-2- thioxo-imidazolidine-4,5-dione... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,3-disubstituted-2- thioxo-imidazolidine-4,5-dione..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,3-disubstituted-2- thioxo-imidazolidine-4,5-dione... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3638939